血清及脑脊液S100B、MBP检测在颅脑损伤中的临床意义

摘要

目的：探讨颅脑损伤后血清及脑脊液中S100B蛋白、髓鞘碱性蛋白(myelin basic protein, MBP)的变化及与颅脑损伤程度的关系。方法：用双抗体夹心酶联免疫吸附试验(enzyme-linked immunosorbent assay, ELISA)检测45例颅脑损伤患者伤后24 h内、7 d的血清、脑脊液中S100B、MBP水平，结合颅脑损伤的程度与对照组(无神经系统疾病史患者10例)进行比较分析。结果：血清中S100B、MBP的水平与脑脊液中S100B、MBP水平均呈正相关，且两者的表达水平随颅脑损伤程度的加重而增加。结论：血清、脑脊液中S100B、MBP可作为判断早期颅脑损伤严重程度的指标，血清检测可替代脑脊液检测及时准确地判断病情。%Objective:To investigate the changes and its clinical significance of S100B, myelin basic protein(MBP) of serum and cerebrospinal fluid in patients with craniocerebral injury. Methods: The concentration of S100B and MBP in serum and cerebrospinal fluid in 45 patients with craniocerebral injury were detected by enzyme-linked immunoabsorbent assay(ELISA) within 24 hours and the seventh day after injury, and were compared with that in 10 patients without diseases of nervous system. The relationship between S100B, MBP concentrations and severity of craniocerebral injury were analyzed. Results:Serum S100B, MBP concentrations and cerebrospinal fluid S100B, MBP concentrations showed a significant positive correlation. Expression level of S100B, MBP increased accompanied by the craniocerebral injury severity. Conclusion: S100B,MBP in serum, cerebrospinal fluid could be a biochemical marker for diagnosis of early craniocerebral injury level, and compared with cerebrospinal fluid, to examine its level in serum can timely and accurately judge the disease.